NASDAQ:ONCY Oncolytics Biotech (ONCY) Stock Price, News & Analysis $1.04 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.03▼$1.0850-Day Range$0.99▼$1.1252-Week Range$0.88▼$2.98Volume94,830 shsAverage Volume286,055 shsMarket Capitalization$79.36 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Oncolytics Biotech alerts: Email Address Oncolytics Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside284.6% Upside$4.00 Price TargetShort InterestHealthy0.85% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.35Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.29) to ($0.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.75 out of 5 starsMedical Sector687th out of 936 stocksPharmaceutical Preparations Industry319th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingOncolytics Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOncolytics Biotech has only been the subject of 1 research reports in the past 90 days.Read more about Oncolytics Biotech's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.85% of the outstanding shares of Oncolytics Biotech have been sold short.Short Interest Ratio / Days to CoverOncolytics Biotech has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncolytics Biotech has recently decreased by 2.69%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldOncolytics Biotech does not currently pay a dividend.Dividend GrowthOncolytics Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ONCY. Previous Next 2.4 News and Social Media Coverage News SentimentOncolytics Biotech has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Oncolytics Biotech this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for ONCY on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows1 people have added Oncolytics Biotech to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.10% of the stock of Oncolytics Biotech is held by insiders.Percentage Held by InstitutionsOnly 6.82% of the stock of Oncolytics Biotech is held by institutions.Read more about Oncolytics Biotech's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Oncolytics Biotech are expected to decrease in the coming year, from ($0.29) to ($0.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncolytics Biotech is -3.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncolytics Biotech is -3.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncolytics Biotech has a P/B Ratio of 3.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Oncolytics Biotech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIWe’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! And how YOU can prepare for the next 2024 BOOM here! About Oncolytics Biotech Stock (NASDAQ:ONCY)Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Read More ONCY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONCY Stock News HeadlinesJuly 26 at 6:22 AM | theglobeandmail.comClosing Bell: Oncolytics Bio up on Thursday (ONC)July 24 at 7:00 AM | prnewswire.comOncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational HighlightsJuly 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.July 23 at 2:48 AM | americanbankingnews.comOncolytics Biotech (NASDAQ:ONCY) Trading Down 1%June 27, 2024 | prnewswire.comOncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer ProgramJune 24, 2024 | prnewswire.comOncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of AbsenceJune 20, 2024 | prnewswire.comOncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic CancerMay 24, 2024 | msn.comAdvancements in Cancer Therapeutics: What to Expect from the Upcoming 2024 Oncology ConferenceJuly 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.May 24, 2024 | finance.yahoo.comOncolytics Biotech Says ASCO Abstracts Highlight Pelareorep's Treatment Potential in Pancreatic CancerMay 24, 2024 | prnewswire.comOncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of ActionMay 16, 2024 | prnewswire.comOncolytics Biotech® Announces Voting Results from the Annual General Meeting of ShareholdersMay 15, 2024 | prnewswire.comOncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer TrialMay 10, 2024 | finance.yahoo.comOncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2024 Earnings Call TranscriptMay 9, 2024 | prnewswire.comOncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational HighlightsMay 9, 2024 | prnewswire.comOncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic CancerMay 8, 2024 | prnewswire.comOncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare ConferenceApril 30, 2024 | finanznachrichten.deUSA News Group: As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up ResponseSee More Headlines Receive ONCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Confirmed)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ONCY CUSIPN/A CIK1129928 Webwww.oncolyticsbiotech.com Phone(403) 670-7377Fax403-283-0858Employees29Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$5.00 Low Stock Price Target$3.00 Potential Upside/Downside+284.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,560,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-110.66% Return on Assets-74.28% Debt Debt-to-Equity RatioN/A Current Ratio8.13 Quick Ratio8.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book3.85Miscellaneous Outstanding Shares76,310,000Free Float76,235,000Market Cap$79.36 million OptionableNot Optionable Beta1.91 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Matthew C. Coffey M.B.A.Ph.D., President, CEO & DirectorMr. Kirk J. Look C.A.CA, Chief Financial OfficerDr. Thomas C. Heineman M.D.Ph.D., Chief Medical OfficerMs. Allison Hagerman P.Eng.P.M.P., Vice President of Product DevelopmentMs. Amy Goodowitz Levin B.S.N.R.N., Vice President of Clinical OperationsJon PattonDirector of Investor Relations & CommunicationMr. John Mark Lievonen BBAC.M., FCA, LLD, MBA, ConsultantMore ExecutivesKey CompetitorsEnlivex TherapeuticsNASDAQ:ENLVOrgenesisNASDAQ:ORGSChembio DiagnosticsNASDAQ:CEMIAkebia TherapeuticsNASDAQ:AKBANature's Sunshine ProductsNASDAQ:NATRView All CompetitorsInstitutional OwnershipVirtu Financial LLCBought 51,889 shares on 5/20/2024Ownership: 0.068%View All Institutional Transactions ONCY Stock Analysis - Frequently Asked Questions How have ONCY shares performed this year? Oncolytics Biotech's stock was trading at $1.35 at the start of the year. Since then, ONCY stock has decreased by 23.0% and is now trading at $1.04. View the best growth stocks for 2024 here. How were Oncolytics Biotech's earnings last quarter? Oncolytics Biotech Inc. (NASDAQ:ONCY) released its quarterly earnings data on Thursday, May, 9th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.02. What is Brad Thompson's approval rating as Oncolytics Biotech's CEO? 2 employees have rated Oncolytics Biotech Chief Executive Officer Brad Thompson on Glassdoor.com. Brad Thompson has an approval rating of 56% among the company's employees. This puts Brad Thompson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. How do I buy shares of Oncolytics Biotech? Shares of ONCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Oncolytics Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncolytics Biotech investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), KushCo (KSHB), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI). This page (NASDAQ:ONCY) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
